GlassScriptPhysician profile
Erin M Stone
NPI 1679734065
$4,158.75
in general payments reported to CMS, 2019-2025
37 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what 85% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.04 · 2020: $95.91 · 2021: $59.09 · 2022: $529 · 2023: $1,120 · 2024: $1,154 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,316 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,315.74 |
| Education | $124.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $741.92 | 2023-2025 | Veozah |
| Abbvie INC. | $698.85 | 2022-2025 | Qulipta, Orilissa, Ubrelvy |
| Sumitomo Pharma America, INC. | $470.27 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $401.75 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $172.95 | 2023-2025 | |
| Novo Nordisk INC | $158.57 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $142.24 | 2024-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $142.06 | 2022-2025 | |
| Myovant Sciences INC. | $104.28 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $101.13 | 2023-2024 | Quviviq |
| Hologic Sales and Service, LLC | $93.03 | 2023-2025 | Myosure Tissue Removal Device, Thinprep 2000 Processor, Aptima |
| Organon LLC | $91.23 | 2023-2025 | Nexplanon |
| Exact Sciences Corporation | $84.13 | 2023-2025 | Cologuard Collection Kit |
| Exeltis, USA INC. | $72.31 | 2023-2025 | Slynd |
| Abbott Laboratories | $64.67 | 2022-2025 | Eterna, Alinity M |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $60.72 | 2025 | Pancreaze |
| Scynexis, INC. | $57.02 | 2022 | |
| Lupin INC. | $56.07 | 2020 | |
| Millicent US INC | $38.69 | 2025 | Intrarosa, Femlyv |
| Coopersurgical, INC. | $37.29 | 2024 | Paragard T 380a, Endosee |
| Shield Therapeutics INC | $33.20 | 2023-2024 | Accrufer |
| Aspira Women'S Health INC | $32.17 | 2024 | Ova1 |
| Amgen INC. | $28.26 | 2022-2024 | Prolia, Evenity |
| Mylan Pharmaceuticals INC. | $27.13 | 2022 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Medtronic, INC. | $23.80 | 2023 | Ligasure |
| Mycovia Pharmaceuticals, INC. | $22.84 | 2023 | Vivjoa |
| Ethicon US, LLC | $22.15 | 2020 | |
| Evofem Biosciences, INC. | $21.94 | 2025 | Phexxi, Solosec, Phexx |
| Minerva Surgical, INC | $20.63 | 2022 | |
| Gynesonics, INC. | $18.77 | 2022 | |
| Amag Pharmaceuticals, INC. | $18.45 | 2019 | |
| Merck Sharp & Dohme LLC | $17.69 | 2020 | |
| Esperion Therapeutics, INC. | $15.61 | 2022 | |
| Cosette Pharmaceuticals INC. | $15.02 | 2025 | Vyleesi |
| Becton, Dickinson and Company | $14.80 | 2023 | Bd Onclarity |
| Bausch Health US, LLC | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.